BiotechTube

cabozantinib + mitoxantrone + prednisone

Phase 3Terminated
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prostate Cancer

Conditions

Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms

Trial Timeline

Mar 1, 2012 → Jan 13, 2015

NCT ID
NCT01522443

About cabozantinib + mitoxantrone + prednisone

cabozantinib + mitoxantrone + prednisone is a phase 3 stage product being developed by Exelixis for Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01522443. Target conditions include Prostate Cancer, Castration Resistant Prostate Cancer, Pain.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01522443Phase 3Terminated

Competing Products

20 competing products in Prostate Cancer

See all competitors
ProductCompanyStageHype Score
NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRTNanobiotixPhase 1/2
36
PemetrexedEli LillyPhase 2
52
5 mg Tadalafil + Placebo + 0.2 mg TamsulosinEli LillyPhase 3
77
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
44
Abemaciclib + Placebo + Abiraterone acetate + PrednisoneEli LillyPhase 2/3
65
eFT508eFFECTOR TherapeuticsPhase 2
44
EnhertuDaiichi SankyoPhase 2
52
Ifinatamab deruxtecan + Docetaxel + Prednisone + Rescue MedicationDaiichi SankyoPhase 3
77
exatecan mesylateDaiichi SankyoPhase 2
52
PLX3397Daiichi SankyoPhase 2
52
Valemetostat + DarolutamideDaiichi SankyoPhase 1
33
Enzalutamide + Placebo + Androgen deprivation therapy (ADT)Astellas PharmaPhase 3
77
EnzalutamideAstellas PharmaPhase 2
52
Enzalutamide + Docetaxel + Prednisolone + PlaceboAstellas PharmaPhase 3
77
EnzalutamideAstellas PharmaPhase 2
52
Enzalutamide + Metformin HydrochlorideAstellas PharmaPhase 1
33
degarelix + GoserelinAstellas PharmaPhase 3
77
Enzalutamide, 160mg, 40 mg soft capsules, once dailyAstellas PharmaPre-clinical
23
enzalutamide + abiraterone acetate + prednisoneAstellas PharmaPhase 2
52
enzalutamide + abiraterone acetate + prednisone + Leuprolide acetateAstellas PharmaPhase 2
52

Other Products from Exelixis

Cabozantinib (XL184) 140 mg + Cabozantinib (XL184) 60 mg + Placebo tablet + Placebo capsuleApproved
82
cabozantinib + prednisonePhase 3
74
Cabozantinib tablets + Everolimus (Afinitor) tabletsPhase 3
74
XL184 + PlaceboPhase 3
74
XL092 + Atezolizumab + RegorafenibPhase 3
74